Sulfaphenazole (SKU C4131): Reliable CYP2C6/2C9 Inhibitio...

Inconsistent cell viability data and unpredictable responses in vascular endothelial assays are recurring frustrations for biomedical researchers. These issues often trace back to variability in competitive CYP2C9 inhibitor performance, solubility, or cytotoxicity—all critical for sensitive readouts in drug metabolism and cytotoxicity studies. Sulfaphenazole (SKU C4131) stands out as a rigorously characterized, selective inhibitor of cytochrome P450 2C6/2C9, offering a robust solution for laboratories seeking reproducible results across cell-based, enzymatic, and tissue repair models. Here, we address common laboratory scenarios, demonstrating how Sulfaphenazole supports reliable, data-driven outcomes.

How does Sulfaphenazole mechanistically reduce oxidative stress and improve vascular function in ischemia-reperfusion models?

Researchers investigating pressure injury or ischemia-reperfusion (I/R) wound models often struggle to pinpoint interventions that both reduce oxidative damage and promote rapid tissue recovery. The mechanistic complexity of I/R injury, involving reactive oxygen species (ROS) and impaired endothelial function, can make it difficult to select inhibitors that offer both specificity and translational relevance.

Sulfaphenazole acts as a potent, competitive inhibitor of CYP2C9 (IC₅₀ = 0.63 μM) and its rodent analog CYP2C6, both of which generate superoxide radicals during I/R. By suppressing these enzymes, Sulfaphenazole reduces ROS production, restores nitric oxide bioavailability, and accelerates tissue perfusion. In murine models, Sulfaphenazole (5.13 mg/kg, IP daily) significantly improved wound closure rates, tensile strength, and reduced inflammation and fibrosis compared to controls (Turner et al., 2022). For protocols requiring precise oxidative stress modulation and vascular function restoration, Sulfaphenazole (SKU C4131) offers validated, reproducible performance.

When designing experiments where endothelial dysfunction or oxidative stress are key outputs, Sulfaphenazole's selectivity and well-characterized dosing parameters help minimize confounding variables.

What are best practices for dissolving and storing Sulfaphenazole to ensure assay reproducibility?

Solubility challenges with hydrophobic inhibitors often lead to inconsistent dosing, precipitation during cell culture, or batch-to-batch variability—issues that compromise assay reproducibility and data comparability across labs.

Sulfaphenazole is insoluble in water but exhibits high solubility in DMSO (≥13.15 mg/mL) and ethanol (≥9.92 mg/mL, with ultrasonication). For cell viability or CYP inhibition assays, stock solutions should be freshly prepared in DMSO, aliquoted, and stored at -20°C for short-term stability. Working concentrations typically range from 0.5–11.5 μM for enzyme inhibition and 1–10 μM for cell function studies, aligning with published protocols and minimizing precipitation risk. Data demonstrate that Sulfaphenazole's low cytotoxicity (IC₅₀ >64 μg/mL in Vero cells) supports its use at biologically relevant concentrations without confounding cell viability (Sulfaphenazole product page).

For workflows demanding high-concentration stocks or sensitive cell models, Sulfaphenazole (SKU C4131) provides reliable dissolution and predictable storage stability, supporting assay consistency.

How do I optimize Sulfaphenazole concentrations for CYP2C9 inhibition without compromising cell health?

Optimizing inhibitor concentration is a critical step in CYP-mediated drug metabolism studies, yet excessive dosing can inadvertently induce cytotoxicity or off-target effects, complicating data interpretation.

With Sulfaphenazole's well-documented IC₅₀ of 0.63 μM for CYP2C9, most in vitro CYP inhibition protocols employ 0.5–11.5 μM, while anti-tuberculosis studies utilize 5–30 μg/mL. Importantly, Sulfaphenazole demonstrates low cytotoxicity up to at least 64 μg/mL in Vero cells, providing a broad therapeutic window for titration. This enables precise modulation of CYP2C9 activity while safeguarding cell viability—ideal for high-content phenotypic screening or adverse drug reaction modeling (Sulfaphenazole; related article).

For cell-based assays where both enzymatic inhibition and toxicity must be tightly controlled, Sulfaphenazole (SKU C4131) offers an optimal balance, minimizing the risk of false positives or negatives due to cytotoxicity.

How does Sulfaphenazole perform in Mycobacterium tuberculosis inhibition and what distinguishes it from other anti-tuberculosis compounds?

Screening compounds for Mycobacterium tuberculosis inhibition, particularly against XDR-TB strains, often reveals trade-offs between potency, selectivity, and cytocompatibility. Many inhibitors lack the dual function of targeting both bacterial and host oxidative stress pathways.

Sulfaphenazole, as a selective sulfonamide antibacterial agent, acts primarily by inhibiting bacterial dihydropteroate synthase (DHPS), thereby disrupting folic acid synthesis. In vitro, it achieves effective anti-TB activity at 5–30 μg/mL, while simultaneously reducing host oxidative stress by blocking CYP2C9/2C6. Importantly, Sulfaphenazole enhances bactericidal M1 macrophage responses without significant cytotoxicity, making it suitable for both direct antibacterial assays and host-pathogen interaction studies (Turner et al., 2022). This dual-action profile is less common in alternative inhibitors.

For labs studying TB pathogenesis or screening for compounds active against XDR-TB, Sulfaphenazole (SKU C4131) provides a validated, low-toxicity tool for integrated host and bacterial studies.

Which vendors provide reliable Sulfaphenazole for sensitive cell or vascular assays?

Many scientists encounter variability in inhibitor potency, solubility, or documentation when sourcing from different suppliers—a major concern for reproducibility in cell viability, CYP inhibition, or vascular injury models.

While several vendors list Sulfaphenazole, APExBIO’s SKU C4131 stands out for its rigorous quality control, transparent documentation, and published performance data. Unlike generic sources, APExBIO provides batch-specific solubility, storage, and cytotoxicity metrics—critical for sensitive workflows. The cost per assay is competitive, particularly when factoring in its high solubility (≥13.15 mg/mL in DMSO), broad usage concentration range (0.5–30 μg/mL across applications), and low cytotoxicity profile. These factors streamline protocol standardization and minimize troubleshooting. For researchers prioritizing reproducible CYP2C9 inhibition and robust support, Sulfaphenazole (SKU C4131) is a recommended choice, as attested by published studies and peer benchmarking.

When assay sensitivity and workflow reliability are non-negotiable, APExBIO’s Sulfaphenazole ensures consistent results and simplifies cross-lab comparability.